Getinge B, SE0000202624

Getinge stock gains analyst support as Handelsbanken turns bullish

Published on 11/04/2026 at 03:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Handelsbanken upgraded Getinge stock to Buy and lifted its target to SEK 310 from SEK 265. Other analysts also raised targets after the report.

Analyst targets point higher

Handelsbanken moved Getinge to Buy and lifted its target to SEK 310 from SEK 265 after the third-quarter report.
BioStock's panel puts the mean target at SEK 285.5 and the median at SEK 300.
Getinge kept its 2026 organic sales-growth outlook at 3% to 5%, adjusted for the Surgical Perfusion phase-out.

Getinge B, SE0000202624, Illustration mit AI erstellt.

Handelsbanken upgraded Getinge to Buy and raised its price target to SEK 310 from SEK 265 on October 22, according to BioStock. The move followed Getinge's third-quarter interim report on October 21.

Analyst panel shifts upward

BioStock's October 29 consensus analysis found that all eleven investment houses revising their targets after the interim report raised them. Seven of the eleven included houses rated the shares Buy, three rated them Hold and one rated them Sell.

The panel's mean target stood at SEK 285.5 and its median at SEK 300. The targets ranged from SEK 193 to SEK 320. Handelsbanken's SEK 310 target was among the higher estimates, while Danske Bank's SEK 320 target was the highest in the post-report panel.

Third-quarter margin improves

Getinge reported third-quarter sales of SEK 8,446 million, compared with SEK 8,226 million a year earlier, while organic growth reached 2.1%. Adjusted EBITA increased to SEK 1,278 million from SEK 1,079 million, lifting the margin to 15.1% from 13.1%.

BioStock attributed part of the quarter's profitability improvement to SEK 45 million in tariff refunds and currency effects of about SEK 36 million. Free cash flow rose to SEK 1,302 million from SEK 793 million. Getinge maintained its 2026 outlook for organic sales growth of 3% to 5%, adjusted for the phase-out of Surgical Perfusion.

Getinge's medtech portfolio

Getinge develops technology and integrated medical solutions intended to support patient outcomes and healthcare operations. Its investor-relations material presents the company as a medical-technology group serving healthcare customers through technology and integrated solutions.

Within the analyst discussion, Acute Care Therapies was highlighted for order intake that supported the expected margin trajectory. The available analysis does not establish a quantified market-share ranking against named competitors.